Osteonecrosis of the femoral head (ONFH) is a debilitating, painful, progressive, and refractory disease that has multiple etiologic risk factors. It is caused by bone cell death, which itself has various causes, leading to femoral head collapse and subsequent osteoarthritis. ONFH primarily influences patients aged from 20 to 50 years; in addition, bilateral hip joints are involved in 75% of patients. Causes include use of corticosteroids, alcohol abuse, previous trauma, hemoglobinopathy, Gaucher disease, coagulopathies, and other diseases. No pharmacologic treatment has been shown to be effective for early ONFH. Outcomes of total hip arthroplasty (THA) for these young and active patients have some drawbacks, primarily due to the young age of these patients, limited lifetime and durability of the implants and their fixation, and the skeletal manifestations of osteonecrosis. As a result of these concerns, there has been an increased focus on early interventions for ONFH aimed at preservation of the native articulation. Core decompression is currently the most widely accepted surgical treatment at the early stage of avascular osteonecrosis (AVN); however, due to limited efficacy, its use has been debated. There is currently no standardised protocol for evaluating and treating osteonecrosis of the femoral head in adults in the United States. Although total hip replacement is the most frequent intervention for treatment of post-collapse (Steinberg stage-IIIB, IVB, V, and VI) osteonecrosis; core decompression is the most commonly offered intervention for symptomatic, pre-collapse (Steinberg stage-IB and IIB) osteonecrosis. Less frequently offered treatments include non-operative, pharmacologic or modality management, osteotomy, vascularised and non-vascularised bone-grafting, hemiarthroplasty, resurfacing and arthrodesis. A promising, minimally invasive, core decompression procedure combined with a mesenchymal stem cell grafting technique which restores vascularity and heals osteonecrotic lesions has become popularised. This procedure is called a bone marrow aspirate concentrate (BMAC) procedure. During a BMAC, mesenchymal stem cells (in the form of concentrated iliac crest bone marrow) are injected through a core decompression tract into the area of necrosis in the femoral head. Most patients with early (pre-collapse) disease have excellent results at 2 to 5 years of clinical follow-up. Patients are weight bearing as tolerated on crutches after the procedure for 6 weeks, and are able to go home on the same day or next day after surgery with minimal pain. We can report on the early, promising results of 300 patients with ONFH treated with BMAC in the United States by two expert hip surgeons with at least 75%-80% survivorship. The care of adults with osteonecrosis of the femoral head is highly variable. This paper will discuss the various non-operative and operative treatment algorithms for ONFH available today. We will also report on a promising, new technique (BMAC), which improves the efficacy of traditional core decompression for early ONFH. The goal of treatment of early ONFH is to avoid THA in young, active patients and this talk will discuss those interventions and treatments which help accomplish that goal

Introduction. Collapse of femoral head associated with end-stage arthritis form hallmark of osteonecrosis of femoral head. Purpose was to assess efficacy of platelet rich plasma following core decompression in early stage of osteonecrosis of femoral head. Methods. Forty consecutive age, sex and BMI-matched patients of osteonecrosis were enrolled for this prospective randomized comparative double blinded clinical study. 19 patients belonged to intervention group (PRP with Core decompression) and 21 to control (Core decompression) group. 8ml of autologous PRP was injected into channels alongwith Calcium Chloride (4:1) after core decompression. Patients were assessed for outcome measures by pain score, functional and Harris Hip scores, Modified Kerboul angle (combined necrotic angle) in MRI. Patients were followed up after 6, 24 weeks and final follow up (mean 10.33 months). Results. There was statistically significant difference in pain score in two groups at different follow ups (p: 0.002, 0.00; 0.001). The difference in function scores in two groups was statistically significant (p: 0.001). There was statistically significant difference in Harris Hip score in two groups at different follow ups (p: 0.021, 0.001; 0.003). Mean increase in modified Kerboul angle in group A was 11.32 (SD±13.00) and in group it was 18.33 (±14.347). 6 (24%) hips in group A and 12 (42%) hips in group B had progression of disease upto final follow up. Conclusions. Core decompression augmented with platelet rich plasma is effective in providing pain relief, improving the functional status and delaying or cessation of progression in early stage of osteonecrosis of hip

Post-traumatic osteonecrosis of the femoral head (ONFH) is a major complication of femoral neck fractures that require numerous solutions. The purpose of the current study is to investigate the effects of platelet-rich plasma (PRP) incorporated autologous granular bones graft for the treatment of pre-collapse stages (ARCO stage II-III) of post-traumatic ONFH. A total of 46 patients were eligible and enrolled into the study. 24 patients were treated with core decompression and PRP incorporated autologous granular bones graft (treatment group: 9 females and 15 males, age range, 16–39 years), and 22 patients with core decompression and autologous granular bones graft (control group: 6 females and 16 males, age range, 18–42 years. During a minimum duration of follow-up of 36 months, multiple imaging techniques including X-ray and computed tomography (CT) scanning were used to evaluate the radiological results, and Harris hip score (HHS) and the visual analogue scale (VAS) were chosen to assess the clinical results. Both treatment group and control group had a significant improved HHS (P < 0.001). The minimum clinically important difference (MCID) for HHS was reached in 91.7% of treatment group and 68.2% of control group (P = 0.0449). HHS in treatment group was significantly higher than control group at the last follow-up (P = 0.0254). VAS score was significantly declined in treatment group when compared with control group (P = 0.0125). Successful clinical results were achieved in 21 of 24 patients (87.5%) in treatment group compared with 13 of 22 patients (59.1%) in control group (P = 0.0284). Successful radiological results were achieved in 19 of 24 patients (79.2%) in treatment group compared with 11 of 22 patients (50%) in control group (P = 0.0380). The survival rates using requirement for further hip surgery as an endpoint were higher in treatment group in comparison to control group (P = 0.0260). The PRP incorporated autologous granular bones graft is a safe and effective procedure for the treatment of pre-collapse stages (ARCO stage II-III) of post-traumatic ONFH

Management of symptomatic osteonecrosis of the hip includes either some type of head preservation procedure or a total hip arthroplasty (THA). In general, once there is collapse of the femoral head, femoral head preservation procedures have limited success. There are a number of different femoral head preservation procedures that are presently performed and there is no consensus regarding which one is most effective. These procedures involve a core decompression with some type of vascularised or nonvascularised grafting of the femoral head. Core decompression with bone grafting of the femoral head with stem cells harvested from the iliac crest and vascularised fibula grafts are the two most popular femoral head preservation procedures. Once the femoral head has collapsed then a THA should be performed when the patient has significant disability. In the past, total hip arthroplasty in osteonecrosis patients was not considered a highly successful procedure because it was performed in younger patients (most patients are younger than fifty years of age) and longevity was limited by wear and osteolysis. The advent of reliable cementless acetabular and femoral fixation and alternative bearing surfaces (i.e. highly crosslinked polyethylene liners) has been associated with improved outcomes and enhanced longevity. THA is considered the procedure of choice even for young patients (less than 30 years old) with collapse of the femoral head and significant pain and disability

Background. Core decompression (CD) is effective to relieve pain and delay the advent of total hip arthroplasty (THA) for osteonecrosis of the femoral head (ONFH). However, the influence of CD on the subsequent THA has not been determined yet. Methods. Literatures published up to and including November 2018 were searched in PubMed, Embase and the Cochrane library databases with predetermined terms. Comparative studies of the clinical outcomes between conversion to THA with prior CD (the Prior CD group) and primary THA (the Control group) for ONFH were included. Data was extracted systematically and a meta- analysis was performed. Results. Overall, five retrospective cohort studies with 110 hips in the Prior CD group and 237 hips in the Control group were included and all the studies were of high quality in terms of Newcastle-Ottawa Scale. No difference in the rate of revision between the two groups showed (RR=1.92, P=0.46) after a minimal two-year follow-up. Postoperative Harris Hip Score were similar between the two groups in all the five studies. Two groups went through similar blood loss (P=0.38). But the operative time in the Prior CD group with tantalum rob was longer than that in the Control group (P=0.006, P<0,001, respectively in two papers). Moreover, intraoperative fracture and osteolysis or radiolucent lines were more likely to occur in the Prior CD group, though there is not statistical difference (RR=7.05, P=0.08; RR=3.14, P=0.05, respectively). Conclusion. The present evidence indicated that prior CD has no inferior effect on the survivorship nor hip scores to the subsequent THA. The operative time in the Prior CD group with tantalum rob was longer than that in the Control group. Attention should also be paid on possible more intraoperative fracture and postoperative osteolysis or radiolucent lines. For any figures or tables, please contact authors directly

Introduction. Core decompression is used in precollapse lesions to forestall disease progression in avascular necrosis (AVN) of femoral head (FH). The author reports a new technique using reverse bone graft technique to effectuate core decompression. Aim. To prevent precollapse in Ficat Type 1&2 and revascularization using synthetic bone graft material. Methods. A 18 year female police trainee with Magnetic Resonance Imaging (MRI) confirming AVN Stage 2 Ficat, clinically painful hip not evident in x-rays consented to undergo this new technique. Reverse bone graft technique with a Coring reamer – Patent 5423823. A minimally invasive technique with lateral 2 cm incision introducing 8.5 mm core reamer to remove a core of bone up to the subchondral bone. The subchondral cyst decompressed and curetted under video recorded Image Intensifier (II). Demarcated avascular bone segment excised and bone graft reversed and inserted with cortical bone acting as a support to prevent collapse and the distal segment augmented using 5 grams of osteoconductive granular synthetic bone graft material based on calcium phosphate hydroxyapatite (HA 2500–5000 μm). Avascular segment histopathologically confirmed AVN. The metaphyseal entry was extrapoliated at the lateral cortex using the combined necrotic angle described by Kerboul in the anteroposterior and lateral views under II. Protected weight bearing for 2 months to prevent stress riser. Biomaterials. HA granules named as GranuMas™ developed under Intensified Research in Priority Areas (IRPA) Research Project (No. 03-01-03-0000-PR0026/05) and invented by the Advance Materials Research Centre (AMREC) and manufactured by GranuLab –Patent P1 20040748 fulfilling the criteria for American Society for Testing and Materials (ASTM) F1185-88(1993) Standards which is ‘Standard Specification for Composition of Ceramic Hydroxyapatite for Surgical Implants’. Derived from Malaysian limestone, ranging from 200–5000 μm gamma sterilized. Results. After 6 months, there was no collapse of subchondral bone and the FH showed revascularization along bone grafted site with viable graft and increased radiotracer activity using 99-Tc MDP Bone Planar Scintigraphy. Clinical analysis follow up at 2 years was descriptive rather than statistical with a x-ray evident incorporated graft and with pain free full range of movement. Discussion. Reduction in intraosseous pressure is achieved by using large bore 8.5 mm coupled with HA granules promoting revascularization. The core tract entering through the metaphyseal region reduces risk of subtrochanteric fracture a potential complication of vascularized fibular grafts and with less morbidity with other treatment methods for osteonecrosis of the femoral head. The concept can be extended in introducing stem cell and biologic material to treat AVN. Conclusion. This technique is minimally invasive and effective in young patients with early stage of FH AVN and has shown revascularization along the bone grafted site

Osteonecrosis (ON) is a debilitating condition that can progress to severe arthritis of the hip. While its exact pathogenesis remains poorly understood, ON is known to be associated with risk factors such as corticosteroid use, alcoholism, and autoimmune disease. Initial radiographic evaluation can reveal sclerotic and cystic changes in the femoral head, which are usually the first clues in diagnosis. Despite these indicators, plain radiographs generally are not sufficient for diagnosis, therefore requiring subsequent magnetic resonance imaging (MRI) studies. Moreover, performing an appropriate assessment of these imaging modalities can help guide the course of treatment. Treatment options are aimed at slowing or stopping the onset of femoral head collapse and include non-operative management, joint preservation procedures, and total joint arthroplasty. Patients at risk of developing ON may benefit from early diagnosis because the characteristic small or medium-sized pre-collapse lesions that are associated with this stage can often be treated with a non-operative or joint preservation approach. However, patients typically present with advanced disease progression and sometimes an unsalvageable joint, thereby necessitating more invasive operative intervention. Surgical modalities include the use of osteotomy, core decompression, vascular grafts, bone graft substitutes, resurfacing, and finally, total hip arthroplasty. Additionally, reports from the past several decades describe improved outcomes and survivorship of these surgical treatment options. Therefore, our purpose is to highlight recent evidence regarding the management of ON with emphasis on the various forms of operative intervention as well as their outcomes

The mean age of patients with osteonecrosis reported in series in our literature is 38 to 53. Thus, performing a total hip replacement on a patient who would need a procedure to last 40–45 years is a concern. Patients with osteonecrosis of the hip require some type of surgical treatment. Without treatment, a large majority of femoral heads in patients even with Ficat stage I osteonecrosis will collapse or become symptomatic. A common scenario is a patient who first presents to the orthopaedic surgeon with severe arthritis secondary to osteonecrosis in one hip and a normal appearing radiograph on the asymptomatic contralateral side. Performing a total hip on the severe arthritic hip is usually not debated. A MRI will commonly show Ficat stage I osteonecrosis on the asymptomatic contralateral hip. Some method of core decompression is a reasonable choice if it is non-steroid induced, small more medially positioned lesion, but not for other Ficat stage 1 lesions or those with more advanced stages. The problem is convincing the patient to have anything done when they are asymptomatic. Because results with total hip replacement for patients with osteonecrosis of the hip have significantly improved, most patients with a symptomatic hip prefer arthroplasty as treatment. Arthroplasty has become the predominant surgical treatment for osteonecrosis of the hip in the United States. 88% of procedures performed on 6,400 patients with osteonecrosis in 2008 reported in the Nationwide Inpatient Sample Database of the hip were total hip replacements. From 16 years earlier, the number of procedures performed had almost doubled and the percentage use of arthroplasty as the performed treatment had increased by 13%. I expect both numbers will continue to increase

The mean age of patients with osteonecrosis reported in series in our literature is 38 to 53. Thus, performing a total hip replacement on a patient who would need a procedure to last 40–45 years is a concern. Patients with osteonecrosis of the hip require some type of surgical treatment. Without treatment, a large majority of femoral heads in patients even with Ficat stage I osteonecrosis will collapse or become symptomatic. A common scenario is a patient who first presents to the orthopaedic surgeon with severe arthritis secondary to osteonecrosis in one hip and a normal appearing radiograph on the asymptomatic contralateral side. Performing a total hip on the severe arthritic hip is usually not debated. A MRI will commonly show Ficat stage I osteonecrosis on the asymptomatic contralateral hip. Some method of core decompression is a reasonable choice if it is non-steroid induced, small more medially positioned lesion, but not for other Ficat stage 1 lesions or those with more advanced stages. The problem is convincing the patient to have anything done when they are asymptomatic. Because results with total hip replacement for patients with osteonecrosis of the hip have significantly improved, most patients with a symptomatic hip prefer arthroplasty as treatment. Arthroplasty has become the predominant surgical treatment for osteonecrosis of the hip in the United States. Eighty-eight percent of procedures performed on 6,400 patients with osteonecrosis in 2008 reported in the Nationwide Inpatient Sample Database of the hip were total hip replacements. From 16 years earlier, the number of procedures performed had almost doubled and the percentage use of arthroplasty as the performed treatment had increased by 13%. I expect both numbers will continue to increase

Introduction:. One method of femoral head preservation following avascular necrosis (AVN) is core decompression and Tantalum Rod insertion. There is, however, a published failure rate of up to 32% at 4 years. The purpose of the present study was to document the clinical and radiological outcome following Total Hip Arthroplasty (THA) subsequent to failed Tantalum Rod insertion. Methods:. Twenty-five failed Tantalum Rod insertions subsequently requiring THA were identified from a prospectively updated database. Seventeen patients met minimum 2 year clinical and radiographic follow-up criteria. St. Michael's Hip (SMH) scores were compared to a matched cohort of patients with THA for AVN without prior Tantalum Rod insertion. Postoperative radiographs were reviewed assessing component alignment, linear wear (Dorr & Wan) and presence of tantalum residue within the joint space. Results:. Nine females and eight males underwent removal of a Tantalum Rod with subsequent THA between May 2005 and March 2010. The mean time between Tantalum Rod insertion and conversion to THA was 23 months (range 6–48) with a mean follow-up of 3.5 years (range 2–5). At each follow-up interval the mean SMH scores were comparable between the two groups (p = 0.445). Femoral stem alignment (p = 0.428) and acetabular cup inclination (p = 0.723) were comparable between groups. Articular tantalum residue was identified in 12 of 17 articulations (7 mild, 3 moderate, 2 severe). Linear wear rates were comparable between the tantalum group (0.07 mm/yr, range 0.01–0.40) and controls (0.07 mm/yr, range 0.02–0.21, p = 0.951). There was no evidence of catastrophic wear. Conclusion:. Tantalum rod conversion to THA in the young adult patient with AVN reveals no early catastrophic sequelae. In the short term, Tantalum Rod insertion does not demonstrate a deleterious effect on subsequent total joint replacement surgery. There is, however, a high rate of retained tantalum debris within the effective joint space with the procedure and thus there is an unknown risk of accelerated articular wear necessitating longer term study

Introduction. The natural history of osteonecrosis of the femoral head (ONFH) is not cleanly understood, but most of them progresse to the joint destruction and requires total hip replacement arthroplasty. There are several head preserving procedure, but no single therapeutic method proved to be effective in preventing progression of the disease. The possibility has been raised that implantation of bone marrow containing osteogenic precursors may be effective in the treatment of this disease. However, there are no long-term follow-up results of cell therapy for ONFH. AS far as we know, there are no reports about bone graft and cell therapy for ONFH. Therefore, we performed a prospective clinical and radiological evaluation on ONFH treated with core decompression combined with autoiliac bone graft and an implantation of autologous bone marrow cells as a therapeutic method of ONFH. Materials and Methods. Sixty-one hips in 52 patients with ONFH were included in this study. The average follow-up of the patients was 68 (60∼88) months. The necrotic lesions were classified according to their size and location, and we compared the results. Results. At the last follow-up, the rate of excellent or good results was 80% (12/15 hips) in the small lesion group, 65% (17/26 hips) in the medium size group, and 28% (6/20 hips) in the large size group. The procedures were a clinical success in 4 of 5 hips(80%) with stage I, 23 of 35 hips (65.7%) with Stage II and 7 hips of 18 hips(38.9%) with stage III and 1 of 3 hips(33.3%) with stage IV. Among the 20 cases with large sized necrotic lesions, 17 cases were laterally located and this group showed the worst outcome with 13 hips (76.5%) having bad or failed clinical results. Conclusions. The outcome of cancellous bone grafting combined with implantation of autologous bone marrow cells differed depending on the size and location of the lesion. The patients who have a large sized lesion or medium sized lateral located lesion would not be considered as a good candidate for head preserving procedure. However for the medium sized lesions, this procedure showed a competent clinical result against other head preserving procedures

INTRODUCTION. Total hip arthroplasty (THA) is not commonly performed in young patients. However, markedly advanced hip disease can cause disabling end-stage arthritis, and THA may be the only available option for pain relief and restoration of function. We report our experience with modern alternative bearing THA in patients younger than 21 years. METHODS. Twenty-one consecutive primary THAs were performed in 18 patients. Pre- and post-operative Harris Hip Scores (HHS) and any postoperative complications were recorded. Radiographs were reviewed for evidence of premature component loosening. Mean patient age at operation was 18 years (range, 13-20). There were 14 females (78%) and 4 males (22%). Nine patients (50%) were Caucasian, 8 (44%) were African-American, and 1 (6%) was Asian. Average follow-up was 45 months (range, 16-85). All patients failed conservative treatment; 15 patients had prior core decompression and bone grafting. Underlying etiology was chemotherapy induced osteonecrosis (7, 33%), steroid induced osteonecrosis (6, 29%), sickle cell disease (5, 24%), and chronic dislocation (3, 14%); 1 patient underwent THA for fracture of a previous ceramic bearing, 1 patient had a slipped capital femoral epiphysis, and 1 patient had idiopathic joint destruction. Components implanted were ceramic/ceramic (14, 67%), metal/highly cross-linked polyethylene (6, 29%), and metal/metal surface replacement (1, 5%). RESULTS. HHS scores improved from 43.6 pre-operatively to 83.6 post-operatively (p<0.001). There were no infections or dislocations, and one patient with acute lymphocytic leukemia experienced post-operative hypotension following bilateral THA which resolved. At time of final follow-up, there was no radiographic evidence of component loosening; one THA was revised for a cracked ceramic liner. CONCLUSION. At intermediate-term follow-up, clinical and radiographic results are favorable following alternative bearing THA in patients under age 21. Long-term follow-up is necessary to assess implant longevity in this patient population

Fresh-frozen allograft bone is frequently used in orthopaedic surgery. We investigated the incidence of allograft-related infection and analysed the outcomes of recipients of bacterial culture-positive allografts from our single-institute bone bank during bone transplantation. The fresh-frozen allografts were harvested in a strict sterile environment during total joint arthroplasty surgery and immediately stored in a freezer at -78º to -68º C after packing. Between January 2007 and December 2012, 2024 patients received 2083 allografts with a minimum of 12 months of follow-up. The overall allograft-associated infection rate was 1.2% (24/2024). Swab cultures of 2083 allografts taken before implantation revealed 21 (1.0%) positive findings. The 21 recipients were given various antibiotics at the individual orthopaedic surgeon’s discretion. At the latest follow-up, none of these 21 recipients displayed clinical signs of infection following treatment. Based on these findings, we conclude that an incidental positive culture finding for allografts does not correlate with subsequent surgical site infection. Additional prolonged post-operative antibiotic therapy may not be necessary for recipients of fresh-frozen bone allograft with positive culture findings.

Cite this article: Bone Joint J 2015;97-B:427–31.

Bone-marrow oedema can occur both in isolation and in association with necrosis of bone, but it has not been shown whether each respond to the same methods of treatment.

We treated 16 patients with isolated oedema and 17, in which it was associated with necrosis of the proximal femur, with the prostacyclin derivative iloprost, which has been shown to be effective in the idiopathic form. The Harris hip score, the range of movement, the extent of the oedema as measured by MRI, pain on a visual analogue scale and patient satisfaction were recorded before and subsequent to treatment.

In both groups, we were able to show a significant improvement (p < 0.001) in these observations during the period of follow-up indicating that iloprost will produce clinical improvement in both circumstances.